Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations

Oncoscience

Volumn 1, Issue 9, 2014, Pages 580-590

  Zhang, Ju ^a   Lou, Xiaomin ^a   Zellmer, Lucas ^b   Liu, Siqi ^a   Xu, Ningzhi ^c   Liao, D Joshua ^b  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CANCER HOSPITAL   (China)

Author keywords

Cancer; Evolution; Mutation; Oncogenes; Tumor suppressor genes

Indexed keywords

EID: 84947808325     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.83     Document Type: Article

References (120)

1. Smalley M, Ashworth A. Stem cells and breast cancer: A field in transit. Nat Rev Cancer 2003; 3:832-844.
2. O'Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett 2014; 344:180-187.
3. Davies PC, Lineweaver CH. Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Phys Biol 2011; 8:015001.
4. Vincent MD. Cancer: beyond speciation. Adv Cancer Res 2011; 112:283-350.
5. Knauss S, Klein A. From aneuploidy to cancer: the evolution of a new species? J Biosci 2012; 37:211-220.
6. Huxley JS. Cancer biology: Comparative and genetic. Biol Rev 1956; 31:474-513.
7. Zhang J, Lou XM, Jin LY, Zhou RJ, Liu SQ, Xu NZ et al. Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. Oncoscience 2014; 1:407-422.
8. Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW et al. Genome chaos: survival strategy during crisis. Cell Cycle 2014; 13:528-537.
9. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002; 2:221-225.
10. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12:745-755.
11. Belizario JE. The humankind genome: from genetic diversity to the origin of human diseases. Genome 2013; 56:705-716.
12. Clark MB, Amaral PP, Schlesinger FJ, Dinger ME, Taft RJ, Rinn JL et al. The reality of pervasive transcription. PLoS Biol 2011; 9:e1000625-doi: 10.1371/journal.pbio.1000625.
13. Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science 2012; 337:1159-1161.
14. Skipper M, Dhand R, Campbell P. Presenting ENCODE. Nature 2012; 489:45.
15. Domazet-Loso T, Klimovich A, Anokhin B, Anton-Erxleben F, Hamm MJ, Lange C et al. Naturally occurring tumours in the basal metazoan Hydra. Nat Commun 2014; 5:4222.
16. Cairns J. Cancer and the immortal strand hypothesis. Genetics 2006; 174:1069-1072.
17. Cairns J. Mutation selection and the natural history of cancer. Nature 1975; 255:197-200.
18. Charville GW, Rando TA. The mortal strand hypothesis: non-random chromosome inheritance and the biased segregation of damaged DNA. Semin Cell Dev Biol 2013; 24:653-660.
19. Yadlapalli S, Yamashita YM. DNA asymmetry in stem cells-immortal or mortal? J Cell Sci 2013; 126:4069-4076.
20. Prehn RT, Prehn LM. A new kink in an old theory of carcinogenesis. Theor Biol Med Model 2013; 10:12.
21. Prehn RT, Prehn LM. Is an immune reaction required for malignant transformation and cancer growth? Cancer Immunol Immunother 2012; 61:963-966.
22. Fabian A, Barok M, Vereb G, Szollosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 2009; 75:67-74.
23. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-111.
24. Subramanian S. Quantifying harmful mutations in human populations. Eur J Hum Genet 2012; 20:1320-1322.
25. Subramanian S. Significance of population size on the fixation of nonsynonymous mutations in genes under varying levels of selection pressure. Genetics 2013; 193:995-1002.
26. Subramanian S. Fixation of deleterious mutations at critical positions in human proteins. Mol Biol Evol 2011; 28:2687-2693.
27. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet 2003; 40:721-728.
28. Lai-Cheong JE, McGrath JA, Uitto J. Revertant mosaicism in skin: natural gene therapy. Trends Mol Med 2011; 17:140-148.
29. Pasmooij AM, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med 2012; 14:167-179.
30. van DE, Pretorius PJ. Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1-a hypothesis. J Inherit Metab Dis 2012; 35:407-411.
31. Bouwman P, Jonkers J. Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors? Clin Cancer Res 2014; 20:540-547.
32. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011; 102:663-669.
33. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res 2008; 68:10021-10023.
34. Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J Cell Biochem 2010; 109:1072-1084.
35. Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 2011; 112:217-253.
36. Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY et al. Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Metastasis Rev 2013; 32:325-340.
37. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339:1546-1558.
38. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-28.
39. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
40. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39:D945-D950.
41. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-421.
42. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505:495-501.
43. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-218.
44. Prehn RT. Cancers beget mutations versus mutations beget cancers. Cancer Res 1994; 54:5296-5300.
45. Sonnenschein C, Soto AM. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J Biosci 2013; 38:651-663.
46. Sonnenschein C, Soto AM, Rangarajan A, Kulkarni P. Competing views on cancer. J Biosci 2014; 39:281-302.
47. Soto AM, Sonnenschein C. Paradoxes in Carcinogenesis: There Is Light at the End of That Tunnel! Disrupt Sci Technol 2013; 1:154-156.
48. Soto AM, Sonnenschein C. One hundred years of somatic mutation theory of carcinogenesis: is it time to switch? Bioessays 2014; 36:118-120.
49. Blagosklonny MV. Molecular theory of cancer. Cancer Biol Ther 2005; 4:621-627.
50. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell 2014; 157:267-271.
51. Cohen RL, Settleman J. From Cancer Genomics to Precision Oncology-Tissue's Still an Issue. Cell 2014; 157:1509-1514.
52. Avesson L, Barry G. The emerging role of RNA and DNA editing in cancer. Biochim Biophys Acta 2014; 1845:308-316.
53. Duesberg P, Mandrioli D, McCormack A, Nicholson JM. Is carcinogenesis a form of speciation? Cell Cycle 2011; 10:2100-2114.
54. Lou X, Zhang J, Liu S, Xu N, Liao DJ. The other side of the coin: The tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle 2014; 13:1677-1693.
55. Fischer AH, Young KA, DeLellis RA. Incorporating pathologists' criteria of malignancy into the evolutionary model for cancer development. J Cell Biochem 2004; 93:28-36.
56. Kreso A, O'Brien CA, van GP, Gan OI, Notta F, Brown AM et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339:543-548.
57. Marusyk A, Polyak K. Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339:528-529.
58. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-1367.
59. Noble RL, Hochachka BC, King D. Spontaneous and estrogen-produced tumors in Nb rats and their behavior after transplantation. Cancer Res 1975; 35:766-780.
60. Noble RL. Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants. Oncology 1977; 34:138-141.
61. Noble RL. Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res 1980; 40:3547-3550.
62. Noble RL, Cutts JH. Mammary tumors of the rat: a review. Cancer Res 1959; 19:1125-1139.
63. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002; 80:175-189.
64. Burrows H. Carcinoma mammae occurring in a male mouse under continued treatment with oestrin. Am J Cancer 1935; 24:613-616.
65. Geschickter CF, Lewis D, Hartman CG. Tumors of the breast related to the oestrin hormone. Am J Cancer 1934; 21:828-859.
66. Mceuen CS. Occurrence of cancer in rats treated with oestrone. Am J Cancer 1938; 34:184-195.
67. Wang C, Tai Y, Lisanti MP, Liao DJ. c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther 2011; 11:615-626.
68. Wu CH, van RJ, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007; 104:13028-13033.
69. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 2008; 3:e2125.
70. Choi PS, van RJ, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ et al. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A 2011; 108:17432-17437.
71. Bellovin DI, Das B, Felsher DW. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol 2013; 734:91-107.
72. Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int 2013; 13:92.
73. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011; 10:57-67.
74. Leontieva OV, Demidenko ZN, Gudkov AV, Blagosklonny MV. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One 2011; 6:e26126.
75. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24:2463-2479.
76. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013; 498:109-112.
77. Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002; 8:1105-1114.
78. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer 2010; 10:232-233.
79. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
80. Blagosklonny MV. Cell immortality and hallmarks of cancer. Cell Cycle 2003; 2:296-299.
81. Tuveson DA, Zhu L, Gopinathan A, Willis NA, Kachatrian L, Grochow R et al. Mist1-KrasG12D knockin mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 2006; 66:242-247.
82. Liao JD, Adsay NV, Khannani F, Grignon D, Thakur A, Sarkar FH. Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer. Histol Histopathol 2007; 22:661-676.
83. Delaval B, Birnbaum D. A cell cycle hypothesis of cooperative oncogenesis (Review). Int J Oncol 2007; 30:1051-1058.
84. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1:157-162.
85. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476:163-169.
86. Goddard MR, Godfray HC, Burt A. Sex increases the efficacy of natural selection in experimental yeast populations. Nature 2005; 434:636-640.
87. Gray JC, Goddard MR. Sex enhances adaptation by unlinking beneficial from detrimental mutations in experimental yeast populations. BMC Evol Biol 2012; 12:43.
88. Zhang J, Lou XM, Jin LY, Zhou RJ, Liu SQ, Xu NZ et al. Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. Oncoscience 14 A.D.; 1:407-422.
89. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12:587-598.
90. Holohan C, Van SS, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-726.
91. Polyak K, Marusyk A. Cancer: Clonal cooperation. Nature 2014; 508:52-53.
92. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wntdriven mammary cancers. Nature 2014; 508:113-117.
93. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 2006; 103:13474-13479.
94. Ben-Jacob E, Coffey DS, Levine H. Bacterial survival strategies suggest rethinking cancer cooperativity. Trends Microbiol 2012; 20:403-410.
95. Aguilar PS, Baylies MK, Fleissner A, Helming L, Inoue N, Podbilewicz B et al. Genetic basis of cell-cell fusion mechanisms. Trends Genet 2013; 29:427-437.
96. Clawson GA. Cancer. Fusion for moving. Science 2013; 342:699-700.
97. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M et al. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer 2012; 131:49-58.
98. Goldenberg DM, Gold DV, Loo M, Liu D, Chang CH, Jaffe ES. Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology. PLoS One 2013; 8:e55324.
99. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013; 18:43-73.
100. Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Anker P, Herrera-Goepfert R, Medina-Velazquez LA et al. Cancer progression mediated by horizontal gene transfer in an in vivo model. PLoS One 2012; 7:e52754.
101. Wang R, Sun X, Wang CY, Hu P, Chu CY, Liu S et al. Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One 2012; 7:e42653.
102. Scudellari M. Genomes gone wild. The Scientist 2014; 28:30-36.
103. Schwarz D, Shoemaker KD, Botteri NL, McPheron BA. A novel preference for an invasive plant as a mechanism for animal hybrid speciation. Evolution 2007; 61:245-256.
104. Mallet J. Hybrid speciation. Nature 2007; 446:279-283.
105. Oren-Suissa M, Podbilewicz B. Evolution of programmed cell fusion: common mechanisms and distinct functions. Dev Dyn 2010; 239:1515-1528.
106. He X, Tsang TC, Pipes BL, Ablin RJ, Harris DT. A stem cell fusion model of carcinogenesis. J Exp Ther Oncol 2005; 5:101-109.
107. Ogle BM, Cascalho M, Platt JL. Biological implications of cell fusion. Nat Rev Mol Cell Biol 2005; 6:567-575.
108. Duelli D, Lazebnik Y. Cell fusion: a hidden enemy? Cancer Cell 2003; 3:445-448.
109. Hadany L, Otto SP. Condition-dependent sex and the rate of adaptation. Am Nat 2009; 174 Suppl 1:S71-S78.
110. Zimmer C. Origins. On the origin of sexual reproduction. Science 2009; 324:1254-1256.
111. Becks L, Agrawal AF. Higher rates of sex evolve in spatially heterogeneous environments. Nature 2010; 468:89-92.
112. Soper DM, King KC, Vergara D, Lively CM. Exposure to parasites increases promiscuity in a freshwater snail. Biol Lett 2014; 10:20131091.
113. Wilson CG, Sherman PW. Spatial and temporal escape from fungal parasitism in natural communities of anciently asexual bdelloid rotifers. Proc Biol Sci 2013; 280:20131255.
114. Boschetti C, Carr A, Crisp A, Eyres I, Wang-Koh Y, Lubzens E et al. Biochemical diversification through foreign gene expression in bdelloid rotifers. PLoS Genet 2012; 8:e1003035.
115. Vineis P, Berwick M. The population dynamics of cancer: a Darwinian perspective. Int J Epidemiol 2006; 35:1151-1159.
116. Li R, Hehlman R, Sachs R, Duesberg P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet Cytogenet 2005; 163:44-56.
117. Lazova R, Chakraborty A, Pawelek JM. Leukocyte-cancer cell fusion: initiator of the warburg effect in malignancy? Adv Exp Med Biol 2011; 714:151-172.
118. Pawelek JM. Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease in cancer. Chin J Cancer 2014; 33:133-139.
119. Garcia-Olmo DC, Picazo MG, Garcia-Olmo D. Transformation of non-tumor host cells during tumor progression: theories and evidence. Expert Opin Biol Ther 2012; 12 Suppl 1:S199-S207.
120. Goldenberg DM. Horizontal transmission of malignancy by cell-cell fusion. Expert Opin Biol Ther 2012; 12 Suppl 1:S133-S139.